We’re charting a new path to advance psychedelic medicine.
There are nearly 1 billion people in the world suffering from a mental health disorder.
Psychedelic therapy has been proven to be a breakthrough mental health treatment. Ketamine, MDMA, and psilocybin are making advancements through the FDA, but the process is inefficient.
We need to make psychedelic therapy accessible, so more people can begin healing now.
That's why we built Maya. We use real world evidence to inform clinical practices, drug development, and regulation to support safe, effective, and accessible psychedelic practices.
Our platform supports three major stakeholders:
Researchers
We give researchers access to unique real world data that can inform clinical trial design and commercialization strategies, and optimize trial outcomes.
Learn moreProviders
We save providers time by automating screening, intake, preparation, and integration. Practice analytics inform greater health outcomes.
Learn moreParticipants
We offer those receiving psychedelic therapy the opportunity to feel safe, gain insight into their healing journey, and learn about their own process.
Coming soon
How Maya works
Together, researchers, providers, and participants using Maya can collaboratively chart real world evidence to advance psychedelic medicine. By bridging the gap between psychedelic research and real world practices, Maya activates decentralized collaboration across the community.
Measurement Based Care Platform for providers.
When charted across time, multi-modal data trends can directly inform strategies for personalizing and optimizing care. Offer a new level of clarity to participants who can visualize their journey and easily engage with forms and assessments.
.png)
Join the provider communityReal World Data Explorer for researchers.
Our Real World Data Platform provides the evidence needed to inform efficient psychedelic studies. Aggregate, derivative population data covering mental health treatments and outcomes are presented in a structured analytics dashboard, allowing you to interrogate and segment historic data in real-time.
.png)
Join the researcher community
World-renowned leaders have partnered with us.
Over the past few years, we’ve earned partnerships with some of the most innovative companies and organizations in the field.
.png)
.png)
We are deeply rooted in the psychedelic and research community.
Our work stems from our background in academic research with Johns Hopkins University through Unlimited Sciences. Following our involvement helping Denver become the first city to decriminalize psilocybin mushrooms, we have become deeply connected with psychedelic practitioners and researchers all over the world.
About Us“
There is much important work to be done in understanding how psychedelic medicines can be utilized safely while maximizing the benefit. I believe the work Maya and its team are doing is exceptional in this regard. It is exactly what is needed to help positively shape the industry while supporting us all to reach a greater stage in human development.
Dr. Dan Engle
Psychiatrist, Founder, Kuya Treatment Center
“
One of Maya’s major contributions is to make it more of the norm for practitioners to collect data, so they are able to demonstrate the value of psychedelic therapy.
.png)
Robin Carhart-Harris
Director of Psychedelics Division, Neuroscape, UCSF
Read our last article
At-Home, Sublingual Ketamine Therapy: The Promises and Pitfalls of Psychedelic Telemedicine
Posted on
November 10, 2022
Listen our last podcast
Ismail Lourido Ali (MAPS): What Legislation in Colorado and Oregon Means for Psychedelic Practitioners
Posted on
December 15, 2022
Keep updated
Subscribe to our newsletter
By completing this form I agree with Maya PBC's terms of service and privacy policy and provide my consent to receive personalized communications from Maya PBC. I understand I can unsubscribe at any time.
